Phase II clinical trial, non-randomized, multicentre, on the combination of gemcitabine, capecitabine and sorafenib (Bay 43-9006) in treatment of patients with unresectable and/or metastatic renal cell carcinoma (RCC).

Trial Profile

Phase II clinical trial, non-randomized, multicentre, on the combination of gemcitabine, capecitabine and sorafenib (Bay 43-9006) in treatment of patients with unresectable and/or metastatic renal cell carcinoma (RCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms SOGUG02-06
  • Most Recent Events

    • 13 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Acronym identified as SOGUG02-06 as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top